Cargando…
A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function
BACKGROUND: Lisdexamfetamine (LDX) and d-amphetamine pharmacokinetics were assessed in individuals with normal and impaired renal function after a single LDX dose; LDX and d-amphetamine dialyzability was also examined. METHODS: Adults (N = 40; 8/group) were enrolled in 1 of 5 renal function groups [...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Therapeutic Drug Monitoring
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949011/ https://www.ncbi.nlm.nih.gov/pubmed/26926668 http://dx.doi.org/10.1097/FTD.0000000000000296 |
_version_ | 1782443365882658816 |
---|---|
author | Ermer, James Corcoran, Mary Lasseter, Kenneth Marbury, Thomas Yan, Brian Martin, Patrick T. |
author_facet | Ermer, James Corcoran, Mary Lasseter, Kenneth Marbury, Thomas Yan, Brian Martin, Patrick T. |
author_sort | Ermer, James |
collection | PubMed |
description | BACKGROUND: Lisdexamfetamine (LDX) and d-amphetamine pharmacokinetics were assessed in individuals with normal and impaired renal function after a single LDX dose; LDX and d-amphetamine dialyzability was also examined. METHODS: Adults (N = 40; 8/group) were enrolled in 1 of 5 renal function groups [normal function, mild impairment, moderate impairment, severe impairment/end-stage renal disease (ESRD) not requiring hemodialysis, and ESRD requiring hemodialysis] as estimated by glomerular filtration rate (GFR). Participants with normal and mild to severe renal impairment received 30 mg LDX; blood samples were collected predose and serially for 96 hours. Participants with ESRD requiring hemodialysis received 30 mg LDX predialysis and postdialysis separated by a washout period of 7–14 days. Predialysis blood samples were collected predose, serially for 72 hours, and from the dialyzer during hemodialysis; postdialysis blood samples were collected predose and serially for 48 hours. Pharmacokinetic end points included maximum plasma concentration (C(max)) and area under the plasma concentration versus time curve from time 0 to infinity (AUC(0–∞)) or to last assessment (AUC(last)). RESULTS: Mean LDX C(max), AUC(last), and AUC(0–∞) in participants with mild to severe renal impairment did not differ from those with normal renal function; participants with ESRD had higher mean C(max) and AUC(last) than those with normal renal function. d-amphetamine exposure (AUC(last) and AUC(0–∞)) increased and C(max) decreased as renal impairment increased. Almost no LDX and little d-amphetamine were recovered in the dialyzate. CONCLUSIONS: There seems to be prolonged d-amphetamine exposure after 30 mg LDX as renal impairment increases. In individuals with severe renal impairment (GFR: 15 ≤ 30 mL·min(−1)·1.73 m(−2)), the maximum LDX dose is 50 mg/d; in patients with ESRD (GFR: <15 mL·min(−1)·1.73 m(−2)), the maximum LDX dose is 30 mg/d. Neither LDX nor d-amphetamine is dialyzable. |
format | Online Article Text |
id | pubmed-4949011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Therapeutic Drug Monitoring |
record_format | MEDLINE/PubMed |
spelling | pubmed-49490112016-08-03 A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function Ermer, James Corcoran, Mary Lasseter, Kenneth Marbury, Thomas Yan, Brian Martin, Patrick T. Ther Drug Monit Original Article BACKGROUND: Lisdexamfetamine (LDX) and d-amphetamine pharmacokinetics were assessed in individuals with normal and impaired renal function after a single LDX dose; LDX and d-amphetamine dialyzability was also examined. METHODS: Adults (N = 40; 8/group) were enrolled in 1 of 5 renal function groups [normal function, mild impairment, moderate impairment, severe impairment/end-stage renal disease (ESRD) not requiring hemodialysis, and ESRD requiring hemodialysis] as estimated by glomerular filtration rate (GFR). Participants with normal and mild to severe renal impairment received 30 mg LDX; blood samples were collected predose and serially for 96 hours. Participants with ESRD requiring hemodialysis received 30 mg LDX predialysis and postdialysis separated by a washout period of 7–14 days. Predialysis blood samples were collected predose, serially for 72 hours, and from the dialyzer during hemodialysis; postdialysis blood samples were collected predose and serially for 48 hours. Pharmacokinetic end points included maximum plasma concentration (C(max)) and area under the plasma concentration versus time curve from time 0 to infinity (AUC(0–∞)) or to last assessment (AUC(last)). RESULTS: Mean LDX C(max), AUC(last), and AUC(0–∞) in participants with mild to severe renal impairment did not differ from those with normal renal function; participants with ESRD had higher mean C(max) and AUC(last) than those with normal renal function. d-amphetamine exposure (AUC(last) and AUC(0–∞)) increased and C(max) decreased as renal impairment increased. Almost no LDX and little d-amphetamine were recovered in the dialyzate. CONCLUSIONS: There seems to be prolonged d-amphetamine exposure after 30 mg LDX as renal impairment increases. In individuals with severe renal impairment (GFR: 15 ≤ 30 mL·min(−1)·1.73 m(−2)), the maximum LDX dose is 50 mg/d; in patients with ESRD (GFR: <15 mL·min(−1)·1.73 m(−2)), the maximum LDX dose is 30 mg/d. Neither LDX nor d-amphetamine is dialyzable. Therapeutic Drug Monitoring 2016-08 2016-07-25 /pmc/articles/PMC4949011/ /pubmed/26926668 http://dx.doi.org/10.1097/FTD.0000000000000296 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Original Article Ermer, James Corcoran, Mary Lasseter, Kenneth Marbury, Thomas Yan, Brian Martin, Patrick T. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function |
title | A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function |
title_full | A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function |
title_fullStr | A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function |
title_full_unstemmed | A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function |
title_short | A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function |
title_sort | single-dose, open-label study of the pharmacokinetics, safety, and tolerability of lisdexamfetamine dimesylate in individuals with normal and impaired renal function |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949011/ https://www.ncbi.nlm.nih.gov/pubmed/26926668 http://dx.doi.org/10.1097/FTD.0000000000000296 |
work_keys_str_mv | AT ermerjames asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT corcoranmary asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT lasseterkenneth asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT marburythomas asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT yanbrian asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT martinpatrickt asingledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT ermerjames singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT corcoranmary singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT lasseterkenneth singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT marburythomas singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT yanbrian singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction AT martinpatrickt singledoseopenlabelstudyofthepharmacokineticssafetyandtolerabilityoflisdexamfetaminedimesylateinindividualswithnormalandimpairedrenalfunction |